Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlamydia vaccine (TVG)
- Development stage
- Preclinical
- Lead developer
- TVG
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Rectal, Intramuscular, Subcutaneous, Intradermal, Topical
01
Overview
A herpesvirus-based viral-vector vaccine developed by The Vaccine Group (TVG) for the prevention of Chlamydia infection in animals. The vaccine utilizes a proprietary herpesvirus vector platform to express Chlamydia antigens, designed to induce protective immunity and reduce the incidence of disease in livestock or companion animals. It is currently in the preclinical stage of development.
- Other names
- Chlamydia vaccine (animal)
02
Targets
MOMP (Major outer membrane protein)
Beyond the preview
Go deeper on Chlamydia vaccine (TVG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chlamydia vaccine (TVG).